HC Lot Release Program guidance
Guidance on the Lot Release Program for Schedule D (biologic) drugs
Current edition
Published April 15, 2026
Current edition
Published April 15, 2026
About this standard
Describes the risk-based Lot Release Program in which each lot of a biologic drug is reviewed, and in some groups tested, before sale in Canada.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
No market listing is published yet.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
Canada
- Lot Release Program for biologic (Schedule D) drugsLot release and sample testing · Sample testing
Related standards: MHRA Responsible Person (import) guidance, EudraLex Volume 4 Annex 16, TGA vaccine batch release, MFDS imported drug management regulation, MFDS national lot release regulation, RDC 669/2022, RDC 670/2022, RDC 900/2024, RDC 944/2024, SFDA lot release policy, Taiwan biological product lot release regulations. See all standards.